Invoice spending in the developed markets will reach over $650
billion by 2022, while net spending will remain flat
• Over the past five years, branded drug net spending in developed markets has risen from $326 billion to $395
billion. In total, 87% of the $69 billion of net growth has come from the United States.
• In 2018, net brand spending will decline in developed markets by 1-3%. This has the effect of reducing net
spending overall on brands in developed markets by approximately $5 billion to a total of $391 billion in 2018.
• While the absolute share of spending from new medicines may be small, control of pricing and access to new
drugs is a key point at which payers can influence drug spending trends for the longer term.
dEvELopEd MARkET BRANd INvoICE ANd NET SpENdINg 2007-2022